Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials

BACKGROUND: The purpose of the study was to evaluate the cost-effectiveness of capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX4) as first-line or second-line chemotherapy in patients with metastatic colorectal cancer. METHODS: On the basis of N...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiroiwa, T, Fukuda, T, Tsutani, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713700/
https://www.ncbi.nlm.nih.gov/pubmed/19491895
http://dx.doi.org/10.1038/sj.bjc.6605114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713700/
https://www.ncbi.nlm.nih.gov/pubmed/19491895
http://dx.doi.org/10.1038/sj.bjc.6605114

Ejemplares similares